Evidence map›Paper›PMID 41396305›Full record

ArticleClinical research in cardiology : official journal of the German Cardiac Society2026

Safety and efficacy of thrombolysis with the EkoSonic Endovascular System for intermediate-high risk pulmonary embolism during on- and off-hours: a multicenter study.

Julia Schulten-Baumer, Abdelrahman Elhakim, Peter Radke, Andreas Schuchert, Björn Stöcker, Matthias Mezger, Elias Rawish, Florian Genske, Thomas Stiermaier, Ingo Eitel and 2 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Julia Schulten-BaumerUniversity Hospital Schleswig-Holstein, Medical Clinic II, University Heart Centre Lübeck, Lübeck, Germany. julia.schulten-baumer@uksh.de.ORCID http://orcid.org/0009-0002-1035-0285
Abdelrahman ElhakimDepartment of Internal Medicine and Cardiology, Schön Clinic Neustadt, Neustadt, Germany.
Peter RadkeDepartment of Internal Medicine and Cardiology, Schön Clinic Neustadt, Neustadt, Germany.
Andreas SchuchertDepartment of Internal Medicine (Cardiology, Rhythmology, Pulmology and Internal Medicine), Friedrich-Ebert Hospital Neumünster, Neumünster, Germany.
Björn StöckerDepartment of Internal Medicine (Cardiology, Rhythmology, Pulmology and Internal Medicine), Friedrich-Ebert Hospital Neumünster, Neumünster, Germany.
Matthias MezgerUniversity Hospital Schleswig-Holstein, Medical Clinic II, University Heart Centre Lübeck, Lübeck, Germany.
Elias RawishUniversity Hospital Schleswig-Holstein, Medical Clinic II, University Heart Centre Lübeck, Lübeck, Germany.
Florian GenskeUniversity Hospital Schleswig-Holstein, Medical Clinic II, University Heart Centre Lübeck, Lübeck, Germany.
Thomas StiermaierUniversity Hospital Schleswig-Holstein, Medical Clinic II, University Heart Centre Lübeck, Lübeck, Germany.
Ingo EitelUniversity Hospital Schleswig-Holstein, Medical Clinic II, University Heart Centre Lübeck, Lübeck, Germany.
Christian FrerkerUniversity Hospital Schleswig-Holstein, Medical Clinic II, University Heart Centre Lübeck, Lübeck, Germany.
Tobias SchmidtDepartment of Internal Medicine and Cardiology, Asklepios Westklinikum Hamburg, Hamburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCatheter-directed thrombolysis using the EkoSonic™ Endovascular System (EKOS) is an established therapy for intermediate-high risk (IHR) pulmonary embolism (PE). However, whether the timing of intervention, during regular working hours (RW) versus (vs.) on duty hours (OD), impacts safety and efficacy outcomes remains unclear.

methodsWe retrospectively analyzed consecutive patients with IHR-PE treated with EKOS-lysis at three German centers between 08/2020 and 12/2023. Patients were grouped by timing into RW and OD group, based on institutional definitions of working hours. The primary endpoint was procedural safety, including in-hospital mortality of any cause and bleeding/non-bleedings complications. Secondary outcome compromised echocardiographic efficacy parameters, including reduction in right ventricular to left ventricular (RV/LV) ratio, systolic pulmonary artery pressure (sPAP), and improvement in tricuspid annular plane systolic excursion (TAPSE).

resultsOf 154 patients, 99 procedures were performed during RW hours, while 55 were done during OD hours. Baseline characteristics were comparable in both groups. Door-to-EKOS time (20.6 (4.8; 44) h vs. 7.2 (4,1; 19) h; p = 0.012) and CT-EKOS time (6.4 (1.3; 20) h vs. 2.3 (1.4; 3.5) h; p = 0.002) were significantly shorter during OD. Overall complication rates were lower OD (20 (20.2%) vs. 4 (7.3%); p = 0.038), with fewer bleeding events (18 (18.2%) vs. 3 (5.5%); p = 0.029). In-hospital mortality was similar (RW 8 (8.1%) vs. OD 2 (3.6%); p = 0.496). Both groups showed significant improvement in echocardiographic parameters with no significant intergroup differences in treatment efficacy.

conclusionEKOS-lysis performed during OD hours is safe and effective, with even fewer complications than during RW hours. These findings support the feasibility and safety of continuous PE-care by an experienced Pulmonary Embolism Response Team irrespective of procedural timing.

Indexed as

Endovascular ProceduresPulmonary EmbolismThrombolytic TherapyAgedEchocardiographyFemaleFibrinolytic AgentsGermanyHospital MortalityHumansMaleMiddle AgedRetrospective StudiesRisk FactorsTime FactorsTreatment OutcomeFibrinolytic AgentsComplicationsEkoSonic Endovascular SystemOutcomeProcedural timingPulmonary embolismThrombolysis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.